



GENERAL PROGRAMME PROVISIONAL

last update: 9 November 2022

DAY 1 (23 November)

07.30-08.50	Registration and welcome coffee	
08.50-10.00	Plenary session A Controlling a pandemic – what are the ethical boundaries? <i>Chaired by Andrea Ammon (ECDC) and ESCAIDE Scientific Committee member Mike Catchpole (ECDC)</i> Keynote speaker: Alena Buyx (Technical University of Munich, Germany)	
10.00-10.15	Message from ECDC Director and ECDC Chief Scientist	
10.30-11.00	Coffee break	
11.00-12.30	Fireside session 1 Implementation science	Fireside session 2 Sexually and community acquired infections, including HIV
12.30-14.30	Lunch break	<i>12.30-13.00 Mindfulness session: be your own coffee or chamomile tea, with Aiga Berke</i> 13.00-13.30 Online only-posters
		<i>13.00-14.00 Career Compass</i> Speakers TBA
13.30-15.00	Fireside session 3 Secondary public health impacts	<i>14.00-15.00 Modelling session: Modelling the future of living alongside COVID-19 in Europe</i> <i>Moderated by Frank Sandmann (ECDC)</i> Speakers: Sebastian Funk (LSHTM, UK), Rebecca Borchering (US CDC), Philippe Beutels (University of Antwerp, Belgium)
15.15-16.00	Poster tour 1 Knowledge for policy and practice Poster tour 2 Emerging and vector-borne diseases Poster tour 3 Respiratory diseases Poster tour 4 Food -and water borne diseases and zoonoses	
16.00-16.30	Coffee break	
16.30-18.00	Plenary session B Refugees and refuge: how to promote and protect the health of displaced people <i>Chaired by the ESCAIDE Scientific Committee members Stine Nielsen (EAN) and Chikwe Ihekweazu (WHO)</i> Speakers: Paul Spiegel (Johns Hopkins Center, US), Aurélie Ponthieu (Médecins Sans Frontières), Elke Jakubowski (Health Policy Europe, Germany), Apostolos Veizis (INTERSOS, Greece)	
18.00-18.15	Daily wrap-up Speakers TBA	
18.30-20.30	Networking cocktail	

NOTES *This is a provisional programme and sessions may change. The final programme will be published closer to the conference dates.*



GENERAL PROGRAMME PROVISIONAL

DAY 2 (24 November)

08.30-09.00	Welcome coffee		
	Plenary session C		
09.00-10.30	Revolutions in vaccination in the age of COVID-19 <i>Chaired by the ESCAIDE Scientific Committee members Adam Roth (ECDC) and Magdalena Rosińska (National Institute of Health, Poland)</i> Speakers: Hanna Nohynek (THL, Finland), Cornelia Betsch (University of Erfurt, Germany), Jeremy Ward (INSERM, France)		
10.30-11.00	Coffee break		
11.00-12.30	Fireside session 4 COVID-19: vaccine effectiveness	Fireside session 5 COVID-19: surveillance action	
12.30-14.30	Lunch break	12.30–13.00 <i>Vitamin groove, with Irina Ljungqvist</i> 13.00–13.30 Online only-posters	12.30–14.00 EAN General Assembly meeting (closed event)
13.30-15.00	13.30-15.00 <i>Eurosurveillance Seminar</i> Communicating science: social media and other means <i>Pitfalls and benefits</i> <i>Moderated by Mario Fafangel (National Institute of Public Health, Slovenia)</i> Speakers: Isabella Eckerle (University of Geneva, Switzerland) and Pampa García Molina (Science Media Centre, Spain)		14.00–15.00 MediPIET session: The role of national FETPs in strengthening countries' capacities for infectious disease prevention and response <i>Moderated by Adam Roth (ECDC)</i> Speakers: Paata Imnadze (NCDC, Georgia), Nada Ghosn (Ministry of Public Health, Lebanon), Nissaf Bouafif ép Ben Alaya (Ministry of Health, Tunisia), Katharina Apers (RKI, Germany)
15.15-16.00	Poster tour 5 COVID-19: vaccination and immunity and promotion Poster tour 7 Antimicrobial resistance and evaluation Poster tour 9 Late-breakers Poster tour 6 Intervention and health Poster tour 8 Surveillance: opportunities		
16.00-16.30	Coffee break		
16.30-18.00	Plenary session D Cutting through the noise: the role of Public Health experts in managing an infodemic <i>Chaired by the ESCAIDE Scientific Committee members Petronille Bogaert (Sciensano, Belgium), Mircea Ioan Popa (Carol Davila University of Medicine and Pharmacy, Romania) and John Kinsman (ECDC)</i> Speakers: Mihai Craiu (Bucharest Mother and Children Hospital, Romania), Neville Calleja (Ministry for Health, Malta), Alma Tostmann (Radboudumc, The Netherlands), Martyna Bildziukiewicz (European External Action Service)		
18.00-18.15	Daily wrap-up		
18.30-20.00	BarCamp		

NOTES This is a provisional programme and sessions may change. The final programme will be published closer to the conference dates.



GENERAL PROGRAMME *PROVISIONAL*

DAY 3 (25 November)

08.30-09.00	Welcome coffee	
09.00-10.30	Plenary session E The COVID-19 pandemic – a surveillance game changer? <i>Chaired by the ESCAIDE Scientific Committee members Vicky Lefevre (ECDC), Bruno Coignard (Santé publique France) and Luísa Peixe (University of Porto, Portugal)</i> Speakers: Silke Buda (RKI, Germany), Søren Alexandersen (SSI, Denmark), Fernando Simon (Ministry of Health, Spain)	
10.30-11.00	Coffee break	
11.00-12.30	Fireside session 6 COVID-19: intervention and health promotion	Fireside session 7 Food -and water borne and vector diseases
12.30-14.30	Lunch	12.30–13.00 <i>Yoga for body and mind stretching, with Maria Keramarou</i>
		13.00–13.30 Online only-posters
		14.00–15.00 Social Sciences Session: Use of social science methods to support the prevention and control of infectious diseases in Europe <i>Moderated by John Paget (Nivel, Netherlands)</i> Speakers: Tamara Giles-Vernick (Institut Pasteur, France), Jens Seeberg (Aarhus University, Denmark), Danny de Vries (Amsterdam Institute for Global Health and Development, the Netherlands), Alice Desclaux (Fann Research Center, Senegal) and John Kinsman (ECDC)
13.30-15.00	Fireside session 8 COVID-19: Surveillance approaches	Fireside session 9 Late breakers
15.15-16.00	Poster tour 10 Surveillance approaches Poster tour 11 Food -and water borne diseases and zoonoses: outbreaks Poster tour 12 COVID-19: burden of disease Poster tour 13 COVID-19: vaccine effectiveness	
16.00-16.30	Coffee break	
16.30-17.00	Final wrap-up	
17.00-17.15	Closing ceremony and awards	

NOTES *This is a provisional programme and sessions may change. The final programme will be published closer to the conference dates.*



FIRESIDE SESSIONS PROGRAMME *PROVISIONAL*

DAY 1 (23 November)

<p>11.00-12.30</p>	<p>Fireside session 1 moderated by <i>Howard Needham</i> Implementation science</p> <ul style="list-style-type: none"> a. Enhanced event-based surveillance: monitoring events during the Ukraine crisis, 2022, <i>Jon Bilbatua</i> b. Collaborative modelling of the future dynamics of COVID-19: the European Forecasting and Scenario Hubs, <i>Katharine Sherratt</i> c. Endemic Zika Virus in Brazil, <i>Laith Yakob</i> d. Effectiveness of Four Vaccines in Preventing SARS-CoV-2 Infection in Kazakhstan Dilyara Nabirova e. An Approach to Developing One Health Field Epidemiology Competencies, <i>Marion Muehlen</i> f. Community-based One Health Approach to Prevent, Detect and Respond to Disease Outbreaks, <i>Muhammad Abdi Haryono</i> 	<p>Fireside session 2 moderated by <i>Aura Georgina Aguirre-Beltran</i> Sexually and community acquired infections, including HIV</p> <ul style="list-style-type: none"> g. Invasive beta-hemolytic streptococcal infections in Finland, 2006-2020: The rise of Lancefield group C/G infections, <i>Dafni Katerina Paspaliari</i> h. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland, <i>Jin-Min Yuan</i> i. Neisseria gonorrhoeae antimicrobial resistance surveillance in the Netherlands: a 10-year overview, <i>Maartje Visser</i> j. Contribution of Sexual Health Centres in hepatitis B detection and control in the Netherlands, <i>Stijn Raven</i> k. Effects of Improving Partner Notification on HIV and gonorrhoea transmission among men who have sex with men in the Netherlands, <i>Maarten Reitsema</i> l. (late breaker) Questionnaire data identifies monkeypox common exposure events at sex-on-premise venues and festivals, England, <i>Alessandra Løchen</i>
<p>13.30-15.00</p>	<p>Fireside session 3 moderated by <i>Julien Beaute</i> Secondary public health impacts</p> <ul style="list-style-type: none"> a. How COVID-19 fast-tracked the development of a national microbiology laboratory database for surveillance in Norway: Success factors, <i>Nina Aasand</i> b. Impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB cases in Ireland, 2011-2021, <i>Sarah Jackson</i> c. A systematic review on the impact of COVID-19 on cervical cancer prevention, diagnosis and treatment, <i>Giulia Dallagiacoma</i> d. The impact of the COVID-19 pandemic and non-pharmaceutical interventions on infectious diseases under national surveillance in the Netherlands from 2020 to Q1 2022, <i>Gijs Klous</i> e. The impact of the COVID-19 pandemic on the transmission of hepatitis B virus among men who have sex with men: a mathematical modelling study, <i>Maria Xiridou</i> f. (late breaker) Estimated averted COVID-19 hospitalisations by the COVID-19 vaccination campaign in the Netherlands, 2 August 2021 through 30 August 2022, <i>Senna van Iersel</i> 	



FIRESIDE SESSIONS PROGRAMME *PROVISIONAL*

DAY 2 (24 November)

<p>11.00-12.30</p>	<p>Fireside session 4 moderated by <i>Mirjam Knol</i></p> <p>COVID-19: vaccine effectiveness</p> <ul style="list-style-type: none"> a. Vaccine effectiveness against COVID-19 and associated death in Alpha and Delta variant outbreaks in long-term care facilities in Germany, <i>Mirco Sandfort</i> b. Primary course and booster vaccine effectiveness against Omicron: Results from a European multicentre study at primary care/ambulatory level, <i>Charlotte Lanièce Delaunay</i> c. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period in the Netherlands: A nationwide study adjusting for chance of exposure, <i>Katja van Ewijk</i> d. COVID-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study, <i>Tobias Homan</i> e. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged 65+ years using electronic health registries; pilot study in four EU/EEA countries, January-February 2022, <i>Alexis Sentis Fuster</i> f. A new challenge for control selection in influenza vaccine effectiveness test-negative design studies in the COVID-19 context: Results from the European I-MOVE multicentre study at primary care level, <i>Esther Kissling</i> 	<p>Fireside session 5 moderated by <i>Nick Bundle</i></p> <p>COVID-19: surveillance action</p> <ul style="list-style-type: none"> a. Comparative risk of cerebral venous sinus thrombosis (CVST) following SARS-CoV-2 vaccination or infection: A national cohort study using linked electronic health records, <i>Columbus Ohaeri</i> b. Risk of SARS-CoV-2 infection among members of a fitness centre chain in Stockholm, Sweden 2020: Is going to the gym risky?, <i>Anine Kongelf</i> c. Bus riding as amplification mechanism for an explosive COVID-19 outbreak after import of SARS-CoV-2 by air travellers, Germany, 2021, <i>Meike Schöll</i> d. Disease severity and outcomes of COVID-19 in cases infected with SARS-CoV-2 Delta and Omicron variants, Skåne region, Sweden, December 2021 - January 2022, <i>Anine Kongelf</i> e. A comparison of COVID-19 critical care admission incidence in Wales by vaccine status, <i>Mai Barry</i> f. Estimate of school-specific reproductive number during weekly screening in the Auvergne-Rhône-Alpes region, France, week 47 to 50, 2021, <i>Elisabetta Colosi</i>
---------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



FIRESIDE SESSIONS PROGRAMME *PROVISIONAL*

DAY 3 (25 November)

<p>11.00-12.30</p>	<p>Fireside session 6 moderated by <i>Harold Noël</i></p> <p>COVID-19: intervention and health promotion</p> <ul style="list-style-type: none"> a. Nosocomial acquisition not associated with increased mortality amongst hospitalised COVID-19 cases in Wales, Feb 2020-Mar 2022, <i>Rubeshkumar Polani</i> b. Incidence rate and risk factors associated with SARS-CoV-2 infection in healthcare workers from three European hospitals, July 2021-April 2022, <i>Camelia Savulescu</i> c. Determinants of healthcare workers' self-reported compliance to infection prevention and control during the COVID-19 pandemic: a cross-sectional study in Dutch residential care facilities for people with intellectual and developmental disabilities, <i>Famke Houben</i> d. Assessing the robustness of SARS-CoV-2 vaccine trial results: systematic review and meta-analysis, <i>Ngoc-Anh Hoang</i> e. Socioeconomic patterns of COVID-19 vaccine uptake in children aged 5-11 in Italy (January - April 2022), <i>Alberto Mateo Urdiales</i> f. The association between SARS-CoV-2 seroprevalence and cross-border mobility for visiting family or friends among Dutch residents of a border province, <i>Demi ME Pagen</i> 	<p>Fireside session 7 moderated by <i>Moa Rehn</i></p> <p>Food and water borne and vector diseases</p> <ul style="list-style-type: none"> a. Regional shift in Pogosta disease incidence during 2021 epidemic in Finland, <i>Eveline Otte im Kampe</i> b. Risk of lymphoma increased after Puumala virus infection in Finland, 2009-2019: a retrospective register-based study, <i>Sohvi Kääriäinen</i> c. An Easter Surprise: Salmonella Typhimurium outbreak linked to chocolate products in the United Kingdom, 2022; a case control study, <i>Amoolya Vusirikala</i> d. International outbreak of Salmonella Typhimurium linked to a chocolate factory in 2022: Belgian findings, <i>Valeska Laisnez</i> e. Whole Genome Sequencing identified a prolonged Salmonella Poona nursery outbreak (2016-2021) in North West England, UK, <i>Joanna Garner</i> f. Climate Warming and increasing Vibrio vulnificus infections in North America, <i>Elizabeth Archer</i>
<p>13.30-15.00</p>	<p>Fireside session 8 moderated by <i>Carlos Carvalho</i></p> <p>COVID-19: Surveillance approaches</p> <ul style="list-style-type: none"> a. Linkage of SARS-CoV-2 sequencing results to the Bavarian surveillance system from January 2021 through February 2022, Germany, <i>Liza Coyer</i> b. Using a novel 'difference-in-differences' method and syndromic surveillance to estimate the impact of media reporting on local healthcare utilisation during an early stage of the COVID-19 pandemic, <i>Aryan Nikhab</i> c. Wastewater surveillance for SARS-CoV-2 closely mirrors incidence data: results from national surveillance in Denmark, October 2021 - May 2022, <i>Oliver McManus</i> d. SARS-CoV-2 Genomic Surveillance: Lessons Learned from the EMERGEN Consortium, France, 2021-2022, <i>Justine Schaeffer</i> e. How do we keep a cohort engaged? Lessons from one year of following up over 44,000 SIREN study participants, UK, <i>Sarah Foulkes</i> f. (late breaker) Surveillance of vaccine effectiveness against mortality from different SARS-CoV-2 variants in southern Sweden between December 2020 and June 2022, <i>Dominik Dietler</i> 	<p>Fireside session 9 moderated by <i>Eleanor McNamara</i></p> <p>Late breakers</p> <ul style="list-style-type: none"> g. Exploring non-viral exposures causatively or contributorily associated with paediatric cases of acute hepatitis of unknown aetiology in the United Kingdom, 2022, <i>Hannah Taylor</i> h. Monkeypox vaccination acceptance among male users of gay dating apps in Europe, <i>Juliana Reyes</i> i. Monkeypox cases in women in England: Characterising transmission routes and monitoring spread outside of GBMSM, <i>Katie Wrenn</i> j. Decreasing mortality linked to SARS-CoV-2 infections in long-term care facilities in Luxembourg: results from national surveillance March 2020-September 2022, <i>Corinna Ernst</i> k. Primary series and booster vaccine effectiveness against the SARS-CoV-2 Omicron variant in a cohort of healthcare workers in Albania, January - May 2022, <i>Iris Finci</i> l. (late breaker) High vaccine effectiveness against severe COVID-19 outcomes during the Omicron era in Luxembourg, December 2021-August 2022, <i>Dritan Bejko</i>



POSTER TOURS PROGRAMME *PROVISIONAL*

DAY 1 (23 November)

15.15-16.00	<p>Poster tour 1 moderated by <i>Gabrielle Schittecatte</i></p> <p>Knowledge for policy and practice</p> <ol style="list-style-type: none"> The COVID-19 pandemic impacted syphilis testing at anonymous consultation clinics in North-Rhine Westphalia state, Germany, 2019-2021, <i>Katja Siling</i> Translating the COVID-19 epidemiological situation into policies and measures: the Belgian experience, <i>Geraldine De Muylder</i> One Health in policy and practice: A UK case study of <i>Corynebacterium ulcerans</i> in a pet and challenges managing human health risk for zoonotic disease where guidance is focused on human cases, <i>Penelope Cresswell-Jones</i> Importance of regional networking in building national FETP: Experience of Lebanon, <i>Zeina Farah</i> Assessment of infection prevention and control in hospitals providing medical care for coronavirus infection (COVID-19) in Bishkek, Osh cities and Chui region, Kyrgyzstan, 2020, <i>Altynai Dzhalmibekova</i> Activation of crisis management structures at the Robert Koch Institute during the COVID-19 pandemic, <i>Ulrike Grote</i>
15.15-16.00	<p>Poster tour 2 moderated by <i>Patrizio Pezzotti</i></p> <p>Emerging and vector-borne diseases</p> <ol style="list-style-type: none"> Modelling the human force of infection of West Nile virus in Europe, <i>Giovanni Marini</i> Risk assessment and preparedness plan development for West Nile Virus (WNV) transmission in the State of Baden-Wuerttemberg, Germany, 2022, <i>Sabrina Nothdurfter</i> Predictors of Lassa fever diagnosis in suspected cases reporting in health facilities: A secondary data analysis of Nigerian surveillance data, 2018-2021, <i>Sandra Mba</i> Spatiotemporal spread of tick-borne encephalitis in the EU/EEA, 2012-2020, <i>Jasper Van Heuverswyn</i> Elevated tick borne encephalitis seroprevalence in blood donors in regions classified as moderately-affected or low -risk in Poland, 2022, <i>Katarzyna Pancer</i> (late breaker) Once more unto the breach: The public health response of an Australian state to the global Monkeypox outbreak 2022, <i>Justine Marshall</i>
15.15-16.00	<p>Poster tour 3 moderated by <i>Katie Palmer</i></p> <p>Respiratory diseases</p> <ol style="list-style-type: none"> Integrated surveillance of SARS-CoV-2 and other human respiratory viruses in a public testing facility in Utrecht, the Netherlands to monitor co-circulation in a susceptible population, <i>Stijn Raven</i> Feasibility to estimate real-time influenza vaccine effectiveness: a pilot study across five European study sites, <i>Marine Maurel</i> The epidemiology of respiratory syncytial virus in children during the COVID-19 pandemic measured by laboratory, clinical and syndromic surveillance in England: a retrospective observational study, <i>Megan Bardsley</i> Differences found in the epidemiology of Tuberculosis (TB) among migrants versus non-migrants in Ireland, 2011-2020, <i>Sarah Jackson</i> A SARS-CoV-2 Omicron outbreak among crew members on a cruise ship in Germany in early 2022, <i>Silja Bühler</i> COVID-19 outbreak in an elderly care home: very low vaccine effectiveness and late impact of booster vaccination campaign, <i>Katja van Ewijk</i>
15.15-16.00	<p>Poster tour 4 moderated by <i>Steen Ethelberg</i></p> <p>Food and water borne diseases and zoonoses</p> <ol style="list-style-type: none"> Timely and reliable outbreak investigation using a non-probabilistic online panel as a source of controls - two parallel case-control studies investigating a Salmonella Braenderup outbreak in Germany, <i>Anna Luczynska</i> An outbreak of Escherichia coli-associated haemolytic uremic syndrome linked to consumption of an unexpected food vehicle, France 2022, <i>Catarina Krug</i> Outbreak investigation of cholera in a peri-urban village of Panchkula district, Haryana, India, 2021, <i>Shivani Gupta</i> Cholera Outbreak Investigation, Ballo Adda Mohalla, Lucknow District, Uttar Pradesh 2021, <i>Surabhi Tripathi</i> Norovirus GII.3[P12] outbreak associated with the drinking-water supply in a rural area in Galicia, Spain, 2021, <i>Camille Jacqueline</i> Impact of COVID-19 restrictions on the epidemiology of Cryptosporidium spp. in England and Wales, <i>James Adamson</i>



POSTER TOURS PROGRAMME *PROVISIONAL*

DAY 2 (24 November)

15.15-16.00	<p>Poster tour 5 moderated by <i>Nathalie Nicolay</i></p> <p>COVID-19: vaccination and immunity</p> <ol style="list-style-type: none"> Seroprevalence of SARS-CoV-2 IgG antibodies and factors associated with neutralizing activity among primary health care workers six months after vaccination rollout in France, <i>Marie Pouquet</i> Direct and indirect vaccination effects on SARS-CoV-2 infection in day-care centers: evaluating the policy for early vaccination of day-care staff in Germany, 2021, <i>Anja Schoeps</i> Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long term care facility residents, <i>Dorothee Obach</i> The effect of hybrid immunity during Omicron variant wave in a European healthcare worker cohort, December 2021 - April 2022, <i>Camelia Savulescu</i> B cell mediated immunogenicity following boosting with the BNT162b2 SARS-CoV-2 vaccine in dialysis patients, Israel, 2021-22, <i>Neta Tuvia</i> Estimating COVID-19 and influenza vaccination coverage in homeless populations; Wales, UK, <i>Gethin Jones</i>
15.15-16.00	<p>Poster tour 6 moderated by TBC</p> <p>Intervention and health promotion</p> <ol style="list-style-type: none"> Deciding about maternal pertussis vaccination: associations between intention, and needs and values in a vaccine-hesitant religious group, <i>Anne de Munter</i> Advocacy and community engagement in TB control: the Kano wellness on wheels (WoW) experience, <i>Mustapha Musa Tukur</i> Hantavirus and Leptospira spp.: Seroprevalence, knowledge and preventive behaviour in seasonal harvesters in Lower Saxony, Germany, 2021, <i>Saskia Schmitz</i> Considerable doubt about rubella screening and vaccination intention among unvaccinated orthodox Protestant women, <i>Anne de Munter</i> Lessons from a protracted iGAS outbreak with added complexity of concurrent scabies outbreak, in a UK residential nursing care facility 2020-2021, <i>Philippa Williams</i> Vaccine confidence among the adult population of Bishkek and Naryn, Kyrgyz Republic, 2021, <i>Marina Malisheva</i>
15.15-16.00	<p>Poster tour 7 moderated by <i>Annick Lenglet</i></p> <p>Antimicrobial resistance</p> <ol style="list-style-type: none"> International patient transfers causing healthcare associated outbreaks of carbapenem-resistant <i>Acinetobacter baumannii</i> in Germany, August - September 2021, <i>Jonathan Baum</i> Emergence of carbapenemase-producing <i>Enterobacteriales</i> causing infection in companion animals, <i>Joana Moreira Da Silva</i> Trends in antibiotic resistance in Portugal: analysis of surveillance data from 2015 to 2020, <i>Vera Manageiro</i> Increasing trends in extended-spectrum β-lactamase production in urine and blood <i>Escherichia coli</i> isolates in Finland in 2008-2019: a retrospective nationwide study, <i>Heikki Ilmavirta</i> Increase in extensively-drug resistant <i>Shigella sonnei</i> infections in Spain, 2021-2022, <i>Camille Jacqueline</i> Failure of scabies treatment: a systematic review and meta-analysis, <i>Felix Reichert</i>
15.15-16.00	<p>Poster tour 8 moderated by <i>Amelie Plymoth</i></p> <p>Surveillance: opportunities and evaluation</p> <ol style="list-style-type: none"> <i>Candida auris</i> in Attica hospitals, Greece: yet another Hospital Acquired Infection, <i>Lida Politi</i> <i>Clostridioides difficile</i> infection surveillance system in Norway: evaluation of the data completeness, 2019-2021, <i>Lea Franconeri</i> Wastewater-based surveillance of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Finland: Informed selection of sites for sampling, <i>Dafni Katerin Paspaliari</i> Evaluation of random-digit-dialing (RDD) recruitment to invite participants for serological tests as a method to obtain a representative sample for general population seroepidemiological surveys, <i>Magdalena Rosinska</i> Evaluation of 17 years of MERIN (Meningitis and Encephalitis register in Lower Saxony, Germany) surveillance program: acceptability survey and data quality assessment, <i>Anna Luczynska</i> Evaluation and comparison of statistical algorithms for monitoring COVID-19 case and death trends in EU/EEA Member States, <i>Chiara Entradi</i>
15.15-16.00	<p>Poster tour 9 moderated by <i>Iro Evlampidou</i></p> <p>Late breakers</p> <ol style="list-style-type: none"> Association between Paediatric Hepatitis Cases of Unknown Aetiology and Adenovirus in Wales, July 2022, <i>Frances Rowley</i> Largest reported outbreak of Crimean-Congo Hemorrhagic Fever (CCHF) in Georgia, 2022, <i>Levan Liluashvili</i> Assessing the short- and long-term impact of behavioural changes and vaccination on the size of a future monkeypox outbreak: A modelling study among men who have sex with men in Belgium, <i>Achilleas Tsoumanis</i> Use of network diagrams to support dynamic assessment of monkeypox transmission patterns in Wales, United Kingdom, 2022, <i>Albert Yung</i> Should we use the 4CMenB (Bexsero®) meningitis vaccine to protect men who have sex with men (MSM) in England against gonorrhoea? A model-based analysis of impact and cost-effectiveness, <i>Dariya Nikitin</i> Feasibility of an ad-hoc participatory daily antigen rapid testing surveillance (DARTS) system for COVID-19 infection in Hong Kong, <i>Nicole Ngai Yung Tsang</i>



POSTER TOURS PROGRAMME *PROVISIONAL*

DAY 3 (25 November)

15.15-16.00	<p>Poster tour 10 moderated by <i>Raquel Medialdea Carrera</i></p> <p>Surveillance approaches</p> <ul style="list-style-type: none"> a. SARS-CoV-2 in schoolchildren during the Delta variant wave August to December 2021– finding from the Danish comprehensive register-based surveillance system, <i>Tjede Funk</i> b. Rapid establishment of a prospective surveillance system for child mortality and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England, <i>Gemma Smith</i> c. Repeated nationwide serosurveillance of SARS-CoV-2 in the Netherlands during the second year of the pandemic: a prospective population-based cohort, <i>Eric Vos</i> d. Investigating opportunities for surveillance of long term chlamydia complications in the Netherlands: a qualitative study, <i>Elke Den Boogert</i> e. Characterisation of measles transmission chains in three outbreaks in the post-elimination phase. Spain 2017-2019, <i>Kevin Bliet-Bueno</i> f. Evaluating severity parameters for scaling up and down public health and social measures during the COVID-19 pandemic in select WHO Member States, <i>Holly Sadler</i>
15.15-16.00	<p>Poster tour 11 moderated by <i>Aine Collins</i></p> <p>Food and water borne diseases and zoonoses: outbreaks</p> <ul style="list-style-type: none"> a. Monophasic <i>Salmonella Typhimurium</i> outbreak linked to chocolate products, Ireland, 2022, <i>Charlotte Salgaard Nielsen</i> b. Successful containment of a <i>Listeria monocytogenes</i> outbreak caused by shredded vegetables, Hesse/Germany, 2021-2022, <i>Laura Becker</i> c. Outbreak of monophasic <i>Salmonella Typhimurium</i> linked to fresh small tomatoes, Sweden, 2021, <i>Karolina Fischerström</i> d. Cluster of dog bite injuries and rabies exposures - Tajikistan, 2022, <i>Rajabali Sharifov</i> e. High fatality rate from probable botulism linked to home canning - Tajikistan, 2021, <i>Sakina Shoeva</i> f. Lassa fever in the East of England: the multiagency response, <i>Eleanor Turner-Moss</i>
15.15-16.00	<p>Poster tour 12 moderated by <i>Lynn Meurs</i></p> <p>COVID-19: burden of disease</p> <ul style="list-style-type: none"> a. Occupational risk factors for SARS-CoV-2 infection amongst healthcare workers in England during the second wave: the SIREN prospective cohort study, September 2020 - April 2021, <i>Edward Monk</i> b. Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway, <i>Jeanette Stålcrantz</i> c. The impact of the COVID-19 pandemic on health-related quality of life in the Dutch population: a preliminary analysis, <i>Cheyenne C.E. van Hagen</i>
15.15-16.00	<p>Poster tour 13 moderated by <i>Alexis Sentis</i></p> <p>COVID-19: vaccine effectiveness</p> <ul style="list-style-type: none"> a. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children 5-11 years old in Italy (January -April 2022), <i>Chiara Sacco</i> b. Monitoring vaccine effectiveness against SARS-CoV-2 infection in a Dutch cohort – The VAccine Study COVID-19 (VASCO), <i>Anne Huiberts</i> c. Vaccine effectiveness of mRNA vaccines against COVID-19 hospitalisation during Omicron circulation in Europe in adults ≥20 years: I-MOVE-COVID-19 and ECDC hospital networks, 27 Dec 2021–31 Mar 2022, <i>Angela Mary C. Rose</i> d. Vaccine effectiveness of BNT162b2 COVID-19 in adolescents: results of a Portuguese population-based cohort study based on electronic health records linkage, <i>Baltazar Nunes</i> e. Relative effectiveness of COVID-19 vaccine booster dose against Delta and Omicron SARS-CoV-2 infection in a European healthcare worker cohort, June 2021- April 2022, <i>Camelia Savulescu</i> f. Effectiveness of BNT162b2 mRNA booster doses and hybrid-immunity against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN study September 2021 to February 2022, <i>Victoria Hall</i>